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Protecting P‑glycoprotein at the blood–
brain barrier from degradation in an Alzheimer’s
disease mouse model
Yujie Ding1, Yu Zhong1, Andrea Baldeshwiler2, Erin L. Abner1,5, Björn Bauer3 and Anika M. S. Hartz1,4,6*

Abstract
Background: Failure to clear Aβ from the brain is partly responsible for Aβ brain accumulation in Alzheimer’s disease
(AD). A critical protein for clearing Aβ across the blood-brain barrier is the efflux transporter P-glycoprotein (P-gp). In
AD, P-gp levels are reduced, which contributes to impaired Aβ brain clearance. However, the mechanism responsible
for decreased P-gp levels is poorly understood and there are no strategies available to protect P-gp. We previously
demonstrated in isolated brain capillaries ex vivo that human Aβ40 (hAβ40) triggers P-gp degradation by activating
the ubiquitin-proteasome pathway. In this pathway, hAβ40 initiates P-gp ubiquitination, leading to internalization
and proteasomal degradation of P-gp, which then results in decreased P-gp protein expression and transport activity
levels. Here, we extend this line of research and present results from an in vivo study using a transgenic mouse model
of AD (human amyloid precursor protein (hAPP)-overexpressing mice; Tg2576).
Methods: In our study, hAPP mice were treated with vehicle, nocodazole (NCZ, microtubule inhibitor to block P-gp
internalization), or a combination of NCZ and the P-gp inhibitor cyclosporin A (CSA). We determined P-gp protein
expression and transport activity levels in isolated mouse brain capillaries and Aβ levels in plasma and brain tissue.
Results: Treating hAPP mice with 5 mg/kg NCZ for 14 days increased P-gp levels to levels found in WT mice. Consistent with this, P-gp-mediated hAβ42 transport in brain capillaries was increased in NCZ-treated hAPP mice compared
to untreated hAPP mice. Importantly, NCZ treatment significantly lowered hAβ40 and hAβ42 brain levels in hAPP
mice, whereas hAβ40 and hAβ42 levels in plasma remained unchanged.
Conclusions: These findings provide in vivo evidence that microtubule inhibition maintains P-gp protein expression
and transport activity levels, which in turn helps to lower hAβ brain levels in hAPP mice. Thus, protecting P-gp at the
blood-brain barrier may provide a novel therapeutic strategy for AD and other Aβ-based pathologies.
Keywords: Blood–brain barrier, P-glycoprotein, Alzheimer’s disease, Brain capillaries, Amyloid beta, Ubiquitinproteasome system
Introduction
One hallmark of Alzheimer’s disease (AD) is the accumulation of neurotoxic amyloid beta (Aβ) in the brain
[1]. This accumulation of soluble and insoluble Aβ
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forms contributes to neurodegeneration and dementia observed in AD [2]. Increasing evidence from recent
studies indicates that Aβ brain accumulation is, in part,
due to impaired Aβ clearance from the brain across the
blood-brain barrier into the blood [3–5]. Results from
multiple studies show that the ATP-driven efflux transporter P-glycoprotein (P-gp) transports Aβ, and thus,
is involved in clearing Aβ from the brain [6–14]. In this
regard, Callaghan et al. used different software docking
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programs to predict P-gp interactions with Aβ. The
obtained models suggest that Aβ40 vertically enters the
central cavity of P-gp [7]. Several studies using tissue
samples from AD patients have shown that blood-brain
barrier P-gp protein expression levels are decreased compared to cognitive normal individuals [15–18]. Recent
data show a 53% reduction (p < 0.01) in P-gp protein
levels in capillaries from AD patient brain samples compared to samples from control individuals [19]. Consistent with decreased P-gp expression levels, results of PET
studies indicate compromised P-gp activity levels in AD
patients [20, 21]. Thus, existing studies support the conclusion that blood-brain barrier P-gp protein expression
and transport activity are decreased in AD. Results from
our own studies using a transgenic mouse AD model
(human amyloid precursor protein (hAPP)-overexpressing mice; Tg2576) support these observations and suggest a link between high hAβ levels and decreased brain
capillary P-gp expression and activity levels in AD [9, 22,
23]. Moreover, we found that hAβ40 causes P-gp degradation in brain capillaries [22, 23]. Specifically, we demonstrated that hAβ40 triggers P-gp degradation through
activation of the ubiquitin-proteasome pathway: first,
P-gp is ubiquitinated; second, P-gp is internalized; and
finally, P-gp is degraded by the proteasome [22, 24]. In
a recent study we showed that preventing P-gp ubiquitination by inhibiting the ubiquitin-activating enzyme E1
protects blood-brain barrier P-gp expression and activity levels and lowers hAβ brain levels in young hAPP
mice [23]. Here, we extend our work and show that dosing 8-week old hAPP mice with the potent microtubule
depolymerization inhibitor nocodazole (NCZ) protects
P-gp protein expression and transport activity and lowers
hAβ brain levels.
Thus, protecting P-gp from internalization and degradation at the blood-brain barrier could be one strategy to
improve Aβ clearance from the brain.

Materials and methods
Experimental design and statistical analysis

Sample sizes (i.e., animal numbers, brain capillary sample size, number of liver tissue samples) were based on
power analyses of preliminary data and past published
work [9, 22, 23, 25]. Sample size and the number of repetitions are reported in the Results section and the corresponding figure legends.
Results are presented as mean ± SEM, or percent
change, as indicated. One-way analysis of variance, with
factor treatment group, was used to assess mean differences in outcomes. Tukey’s HSD post-hoc test was used
to preserve the family-wise Type 1 error rate at 5%.
Post hoc tests were not performed when the omnibus
F statistic was not significant. Statistical analyses were
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completed using SAS 9.4® (SAS Institute, Inc.; Cary, NC,
USA).
Animals

The Institutional Animal Care and Use Committee at
the University of Minnesota (Protocol #1110A05865,
principal investigator; PI: Hartz, AMS) approved all
animal experiments, which were conducted in accordance with AAALAC regulations, the Guide of the Care
and Use of Laboratory Animals of the NIH, and the US
Department of Agriculture Animal Welfare Act.
Male wild type mice (WT; RRID: IMSR_TAC:2789;
n = 10) and male transgenic hAPP-overexpressing
mice (Tg2576 strain; 129S6.CgTg(APPSWE2576Kha;
RRID:IMSR_TAC:2789; n = 45) were acquired from
Taconic Farms (Germantown, NY, USA). Mice were
received at age 8–12 weeks and were housed individually in an AAALAC-accredited temperature-and-humidity-controlled vivarium (23 °C, 35% relative humidity,
12 h light-dark cycle) and allowed to habituate to their
environment for two weeks prior to experiments. Mice
had ad libidum access to tap water and standard rodent
feed (Harlan Teklad Chow 2918, Harlan Laboratories
Inc., Indianapolis, NJ, USA). Mice used for experiments
were 10–14 weeks old and had a mean body weight of
27.4 ± 1.1 g (mean ± SD) and 27.6 ± 2.7 g (mean ± SD) for
WT and hAPP strains, respectively.
Chemicals

Antibodies against β-actin (ab8226; RRID: AB_306371),
human Aβ40 (ab12265; RRID:AB_298985), human Aβ42
(ab12267; RRID:AB_298987), as well as cyclosporin A
(CSA; ab120114) were purchased from Abcam (Cambridge, MA, USA). Modified Dulbecco’s phosphate
buffered saline (DPBS) with 0.9 mM Ca2+ and 0.5 mM
Mg2+ was purchased from HyClone (Logan, UT, USA).
Complete™ protease inhibitor was purchased from
Roche (Mannheim, Germany). C219 antibody against
P-gp was purchased from ThermoFisher (MA126528;
RRID:AB_795165; Waltham, MA, USA). FluoresceinhAβ42 [fluorescein-Aβ(1− 42)] was purchased from
rPeptide (Bogart, GA, USA). [N-(4-nitrobenzofurazan7-yl)-D-Lys8]-cyclosporin A (NBD-CSA) was customsynthesized by R. Wenger (Basel, Switzerland; [26]).
PSC833 was a kind gift from Novartis (Basel, Switzerland). Nocodazole, the ALT Assay Kit (MAK052), CelLytic™ M, Ficoll® PM 400, bovine serum albumin and
all other chemicals were purchased at the highest grade
from Sigma-Aldrich (St. Louis, MO, USA).
NCZ dosing

Mice were randomly divided into four treatment groups
(Group 1: WT mice treated with vehicle, n = 10; Group
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2: hAPP mice treated with vehicle, n = 15; Group 3: hAPP
mice treated with nocodazole (NCZ), n = 15; and Group
4: hAPP mice treated with cyclosporin A (CSA) and
NCZ, n = 15). Mice were treated for a total of 14 days; the
dosing regimens for NCZ and CSA are shown in Table 1.
The dosing regimen and length of the treatment are
based on our previously published study and preliminary
experiments using NCZ [23]. Briefly, mice in Groups 1
and 2 were treated daily with vehicle (i.p.) every three
days for the entire duration of the experiment. Mice in
Groups 3 and 4 were treated with 5 mg/kg of NCZ (i.p.)
every 3 days (days 1, 4, 7, 10, and 13). On days when no
NCZ was given, mice in Group 3 were treated with vehicle (p.o.) and mice in Group 4 were treated with 25 mg/
kg CSA (p.o.).
Blood and tissue collection

At the end of the 14-day treatment period, all mice were
euthanized by CO2 inhalation and decapitated; brain tissue, trunk blood, and liver were collected from each animal. Blood was stored in heparinized tubes and plasma
was extracted from blood by centrifugation at 5000g for
5 min at 4 °C. Brain and liver tissue were frozen in liquid
nitrogen at the time of collection and stored at – 80 °C
until further analysis.
ALT assay

Alanine aminotransferase activity (ALT) in liver tissue
lysate was measured using an ALT activity kit (MAK052;
Sigma-Millipore, St. Louis, MO, USA) according to the
manufacturer’s instructions. Briefly, from each mouse
40 mg of collected liver tissue were homogenized in 300
µl of ALT Assay Buffer using a Power Gen 125 tissue
homogenizer (Thermo Fisher Scientific, Hampton, NH,
USA). Homogenized liver samples were centrifuged at
15,000g for 15 min at 4 °C. Supernatant containing ALT
from each liver sample was diluted 1:100 for ALT activity determination. 20 µl of the diluted samples was pipetted in duplicates onto a 96-well microplate. Wells were
treated with ALT Master Mix solution. Changes in colorimetric intensity was measured at 570 nm over 30 min (5
Table 1 Treatment schedule
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min reading intervals, 37 °C) using a Synergy™ H1 Hybrid
Multi-Mode Reader (BioTek, Winooski, VT, USA).
The amount of generated pyruvate, a measure of ALT
activity, was determined using a standard curve. ALT
activity was calculated using Eq. (1).
ALTActivity = 

(nmolofALT × DilutionFactor)
 

Tfinal − Tinitial × VolumeofSample

(1)
ALT activity is reported as nmole/min/ml = milliunit/
mL (mU/ml), where one milliunit (mU) of ALT is defined
as the amount of enzyme that generates 1.0 nmole of
pyruvate per minute at 37 °C.
Tissue harvest and brain capillary isolation

Brain capillaries were isolated as previously described
[22, 23, 27]. Following euthanasia with CO2, brains were
collected, dissected, and cleaned of meninges. Frontal
cortex tissue (~ 10 mg/brain) was collected, snap frozen
in liquid nitrogen, and stored at − 80 °C for Aβ analysis.
The remaining brain tissue was homogenized in C
 a2+/
2+
Mg -containing DPBS supplemented with 5 mM D-glucose and 1 mM sodium pyruvate. The brain homogenate was mixed with a 15% Ficoll→ PM 400 solution and
centrifuged at 5,800 g for 20 min at 4°C to yield capillary-containing pellets. The pellets were separated and
resuspended in 1% BSA-DPBS solution and the capillary
suspension was filtered through a 300 µm nylon mesh
and then passed through a glass bead column (glass bead
diameter: 0.45–0.5 mm) with 1% BSA-DPBS. Capillaries
were washed off the glass beads with 1% BSA-DPBS. The
resulting capillary suspension was centrifuged at 1,500 g
for 3 min at 4ºC and the pellet was washed three times
with DPBS. Isolated capillaries were used for transport
experiments, isolation of capillary crude membranes, or
stored for later analysis at − 80 ºC.
Capillary Crude membrane isolation

Capillary crude membranes were obtained from freshly
isolated brain capillaries as described in previous studies [27]. Isolated brain capillaries were homogenized in a
cell lysis buffer (CellLytic™ M, Sigma-Aldrich, St. Louis,
MO, USA) containing Complete™ protease inhibitor
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(Sigma-Aldrich, St. Louis, MO, USA). The capillary
homogenate was centrifuged at 10,000g for 15 min at 4
°C to separate organelles and cellular debris. The supernatant was then centrifuged at 100,000g for 90 min at 4°C
to obtain a pellet containing brain capillary crude membranes. Crude membranes were resuspended in buffer
and stored at − 80 °C.
Western blotting

Protein expression levels were determined by Western
blot analysis as described in previous studies [9, 22]. Protein concentrations of brain capillary crude membrane
samples and brain lysate samples were determined with
the Bradford assay. The Invitrogen N
 uPage® Bis-Tris
electrophoresis and blotting system was used to perform all Western blots. Following protein transfer, blotting membranes were blocked and incubated overnight
with the primary antibody (P-gp: C219, 1 µg/ml; hAβ40:
1 µg/ml; hAβ42: 1 µg/ml; β-Actin: 1 µg/ml). Blotting
membranes were washed and incubated for 1 hour with
horseradish peroxidase-conjugated ImmunoPure secondary IgG antibody (1:5000, 0.15 µg/ml; Thermo Fisher
Scientific, Waltham, MA, USA). Proteins were detected
using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Waltham, MA, USA).
Protein bands were visualized using a Bio-Rad ChemiDoc XRS + gel documentation system. Optical density
and digital molecular weight analyses were performed
using Image Lab 5.0 software from Bio-Rad Laboratories (RRID:SCR_014210) and a molecular weight marker
(RPN800E; GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK). Linear adjustments of contrast and
brightness were applied to entire Western blot images.
Nonlinear adjustments were not applied.
P‑gp transport activity and p‐gp‐mediated hAβ42
transport

P-gp transport activity levels and P-gp-mediated Aβ
transport were determined as previously described [9,
28, 29]. To determine P-gp transport activity, freshly isolated brain capillaries were incubated with 2 µM of the
P-gp-specific substrate NBD-cyclosporin A (NBD-CSA)
in DPBS for 1 hour. To assess P-gp-mediated hAβ42
transport activity, brain capillaries were incubated with 5
µM fluorescein-hAβ42 in DPBS for 1 hour. Images of 10
capillaries per treatment group were captured by confocal microscopy using the 488 nm line of an argon laser
of a Leica TCS SP5 confocal microscope with a 63 × 1.2
NA water immersion objective (Leica Instruments, Wetzlar, Germany). NBD-CSA fluorescence in the capillary lumen was measured in each image using Image J
v.1.48v (Wayne Rasband, NIH, USA; RRID:SCR_003070).
Specific, luminal NBD-CSA or fluorescein-hAβ42
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fluorescence were measured as the difference between
total luminal fluorescence and fluorescence in the presence of 5 µM PSC833, a P-gp-specific inhibitor [9, 28, 29].
Aβ immunostaining of brain capillaries

Freshly isolated brain capillaries were immunostained
for hAβ40 and hAβ42 using a method described in previous studies [9]. Mouse brain capillaries were fixed with
3% paraformaldehyde/0.25% glutaraldehyde for 30 min
at room temperature and subsequently washed with
PBS. Fixed capillaries were treated with 0.5% Triton
X-100 for 30 min, washed with PBS and blocked with 1%
BSA/DPBS for 60 min. Capillaries were incubated overnight using a 1:250 dilution (4 µg/ml) of primary rabbit
polyclonal antibody to human Aβ1-40 (hAβ40; ab12265,
Abcam, Cambridge, MA, USA; RRID:AB_298985) or
primary rabbit polyclonal antibody to human Aβ142 (hAβ42; ab12267, Abcam, Cambridge, MA, USA;
RRID:AB_298987). Capillaries were washed with 1%
BSA/PBS for 60 min and incubated with secondary
Alexa-Fluor 488-conjugated goat anti-rabbit IgG (1:1000,
1 µg/ml; Invitrogen, Carlsbad, CA, USA; RRID:AB
2,576,217) for 1 h at 37 °C. Nuclei were counterstained
with 1 µg/ml DAPI (MilliporeSigma, Burlington, MA
USA;RRID:SCR_014366). Immunofluorescence of hAβ40
and hAβ42 was visualized by confocal microscopy (Leica
TCS SP5 confocal microscope, 62 × 1.2 NA water objective, Leica Instruments, Weltzar, Germany). Brain capillary plasma membrane immunofluorescence of hAβ40
and hAβ42 was measured for each capillary with ImageJ
software v1.48 as previously described [9, 23]. A 10 × 10
grid was superimposed on each image and fluorescence
measurements of capillary membranes were taken
between intersecting grid lines. The fluorescence intensity for each capillary was the mean of three measurements per capillary.
hAβ40 and hAβ42 ELISA

Human Aβ40 and Aβ42 levels in plasma and brain samples were determined by ELISA following the manufacturer’s protocols (KHB3482 (sensitivity: < 6 pg/ml) and
KHB3442 (sensitivity: < 10 pg/ml); Invitrogen, Camarillo, CA, USA). Plasma samples were centrifuged at
5000 g for 5 min at 4 °C, and then diluted with standard
diluent buffer provided in the kit (hAβ40: 1:50 dilution;
hAβ42: 1:4 dilution). Brain samples were homogenized
in guanidine Tris-HCl buffer (5 M, pH 8) and diluted in
DPBS containing 5% BSA and 0.03% Tween-20 (hAβ40:
1:20 dilution; hAβ42: 1:5 dilution). Diluted samples were
centrifuged at 16,000g for 20 min at 4 °C; the supernatant was analyzed by ELISA. Absorbance (450 nm) was
measured using a Synergy™ H1 Hybrid Multi-Mode
Reader (BioTek, Winooski, VT, USA). A standard curve
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was plotted using Gen5™ software v2.07 to determine the
concentration of hAβ40 and hAβ42 in plasma and brain
samples; values obtained at 450 nm were corrected for
background absorbance; four parameter logistic ELISA
curve fitting was used.

Results
We previously reported that hAβ40 triggers degradation
of P-gp at the blood-brain barrier [22, 23]. We found that
hAβ40 activates the ubiquitin-proteasome system, which
leads to internalization and proteasomal degradation of
the transporter [22, 24]. Further, we showed that inhibition of intracellular trafficking with microtubule inhibitors blocks proteasomal degradation of P-gp in isolated
brain capillaries [22]. The present study extends these
findings to an in vivo strategy designed to protect P-gp
from degradation by blocking transporter internalization.
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b

Effect of NCZ on P‑gp protein expression and transport
activity

Microtubule inhibitors, such as nocodazole, have been
shown to disrupt intracellular trafficking and internalization of membrane proteins, such as P-gp [22, 30]. In the
present study, we used transgenic hAPP mice (Tg2576
model), one of the best characterized AD models that
overexpresses human APP which leads to Aβ brain
deposits [31]. At 8-weeks of age, hAPP mice have accumulation of human Aβ in the brain and show reduced
P-gp protein expression and transport activity at the
blood-brain barrier [9, 23]. We dosed 8-week old hAPP
mice (n = 15) with the microtubule inhibitor nocodazole (NCZ; 5 mg/kg, i.p.) once every three days for two
weeks (Table 1). A second group of hAPP mice received
NCZ once every three days and on the two days between
NCZ injections, this group of mice also received the P-gp
inhibitor cyclosporin A (CSA; 25 mg/kg, p.o.; n = 15).
Note that the group of NCZ-CSA-treated hAPP mice
served as a control for P-gp transport activity to account
for NCZ-treatment effects that depend on P-gp transport
activity. Wild Type (WT; n = 10) mice and hAPP control
mice (n = 15) received vehicle.
We found that after 14 days of treatment, P-gp protein expression levels in brain capillary membranes
from NCZ-treated hAPP mice were comparable to those
observed in WT mice (Fig. 1a). The same effect was
observed in NCZ-CSA-treated mice. In contrast, vehicle-treated hAPP mice showed significantly decreased
P-gp protein expression levels. Western blots were
quantified by optical density analysis and normalized to
β-actin (Table 2). Optical density measurements of P-gp
protein expression levels (n = 3, normalized to β-actin,
SEM, p-value) are reported as percentage relative to
WT control mice: hAPP: 51 ± 3% (Δ=-49%; p = 0.0093;

c

Fig. 1 Effect of NCZ on P-gp protein expression and transport
activity. a Western Blot for P-gp showing bands for brain capillary
membranes isolated from vehicle-treated wild-type (WT),
vehicle-treated hAPP mice, hAPP mice dosed with 5 mg/kg NCZ and
hAPP mice dosed with a combination of NCZ and CSA (5/25 mg/kg).
β-Actin was used as protein loading control; pooled tissue (WT: 10
mice; hAPP: 15 mice; hAPP-NCZ: 15 mice, hAPP-NCZ/CSA: 15 mice).
Data were normalized to β-Actin. b Representative confocal images
showing accumulation of P-gp-specific substrate NBD-CSA in isolated
brain capillaries from WT, hAPP, hAPP-NCZ and hAPP-NCZ/CSA mice
after a 1 hour incubation (steady state; 2 µM NBD-CSA). c Data after
digital image analysis using ImageJ. Specific NBD-CSA fluorescence
is the difference between total luminal NBD-CSA fluorescence and
NBD-CSA fluorescence in the presence of the P-gp-specific inhibitor
PSC833 (5 µM). Statistics: Data per group are given as mean ± S.E.M.
for 10 capillaries from one preparation [pooled tissue: WT (10 mice),
hAPP (15 mice), hAPP-NCZ (15 mice), hAPP-NCZ/CSA (15 mice)].
Shown are arbitrary fluorescence units (scale 0–255). ***, significantly
lower than control, p < 0.001
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Table 2 Western blot analysis of P-gp protein expression levels
in brain capillaries isolated from WT and hAPP mice (Fig. 1a)
Protein

Wild Type

hAPP

hAPP-NCZ

hAPP-NCZ/CSA

P-gp

100 ± 13

51 ± 3*

102 ± 7

91 ± 6

Data were obtained from optical density measurements and were normalized to
β-actin levels; values are given as %control ± SEM (n = 3)
*Indicates statistical significance determined at the 0.05 level for each endpoint
compared to control using Dunnett’s many-to-one t-test

Tukey’s HSD post hoc test); hAPP-NCZ: 102 ± 7%
(Δ = 2%; p = 1.00; Tukey’s HSD post hoc test), and hAPPNCZ/CSA: 91 ± 6% (Δ=-9%; p = 0.83; Tukey’s HSD post
hoc test).
We also determined P-gp transport activity levels by
live-cell imaging of isolated brain capillaries according to
a previously established protocol [9, 22, 25, 28]. Briefly,
freshly isolated brain capillaries are transferred onto a
glass cover slip and incubated for 1 hour with the fluorescent P-gp substrate NBD-cyclosporin A (NBD-CSA,
2 µM). Brain capillaries are then imaged using confocal
microscopy and fluorescence of NBD-CSA accumulation
in the capillary lumen is measured by quantitative image
analysis using ImageJ. Changes in luminal NBD-CSA
fluorescence compared to WT control indicate changes
in P-gp transport activity. Thus, luminal NBD-CSA fluorescence is an indirect measure of P-gp transport activity. Figure 1b shows representative confocal images of
brain capillaries isolated from WT mice, hAPP mice,
NCZ-treated hAPP mice, and hAPP mice treated with
the combination of NCZ-CSA after a one-hour exposure
to 2 µM NBD-CSA. Image analysis shows that specific
luminal NBD-CSA fluorescence levels in the lumens of
brain capillaries from hAPP mice were decreased by 76%
(p < 0.0001; Tukey’s HSD post hoc test) compared to levels
in capillaries from WT mice (Fig. 1c). Luminal NBD-CSA
fluorescence levels in brain capillaries from NCZ-treated
hAPP mice were increased by 26% relative to levels measured in capillaries from WT mice (p = 0.03; Tukey’s HSD
post hoc test). Compared to WT mice, luminal NBDCSA fluorescence levels in brain capillaries from NCZtreated hAPP mice that received CSA were reduced by
92%. This decrease in luminal NBC-CSA fluorescence is
comparable to that found in vehicle-treated hAPP mice
(p < 0.0001; Tukey’s HSD post hoc test). Thus, we found
decreased luminal NBD-CSA fluorescence in brain capillaries isolated from untreated hAPP mice and NCZCSA-treated hAPP mice, whereas luminal NBD-CSA
fluorescence levels in brain capillaries from NCZ-treated
hAPP mice were similar to those observed in capillaries
from WT mice. Note that we previously published a control experiment showing that nocodazole alone has no

effect on P-gp protein expression and transport activity
in isolated brain capillaries [22]. Thus, it is unlikely that
the observed effects are due to nocodazole-mediated
induction of P-gp protein expression.
In summary, the findings described in Fig. 1 show that
treating hAPP mice with NCZ for two weeks restored
P-gp protein expression and transport activity levels in
brain capillaries. The data presented here together with
our previously published work suggest that NCZ likely
prevents P-gp internalization and degradation [22, 23].
Effect of NCZ on p‐gp‐mediated Aβ transport in hAPP mice

Next, we assessed P-gp-mediated transport of fluorescent labeled hAβ42 in isolated brain capillaries from
mice in all four treatment groups. In these experiments,
isolated brain capillaries were incubated to steady state
with fluorescein-hAβ42 (FL-hAβ42; 5 µM) for 1 hour
before we imaged the capillaries with a confocal microscope. FL-hAβ42 fluorescence in capillary lumens was
analyzed by quantitative image analysis [9, 22, 25, 28].
Figure 2a shows representative confocal images of isolated brain capillaries incubated to steady state with
5 µM FL-hAβ42. These images show reduced luminal
FL-hAβ42 fluorescence in capillaries from vehicle-treated
hAPP mice and in hAPP mice treated with NCZ-CSA
compared to WT and NCZ-treated hAPP mice. Note
that CSA is a competitive P-gp inhibitor, and therefore,
P-gp-mediated FL-hAβ42 transport is reduced in isolated
capillaries from hAPP mice that received the combination NCZ-CSA. Image analysis shows that in capillaries
from hAPP mice, luminal FL-hAβ42 fluorescence was
decreased by 68% (p = 0.0023; Tukey’s HSD post hoc test)
compared to capillaries from WT mice (Fig. 2b). In brain
capillaries from NCZ-CSA-treated hAPP mice, luminal
FL-hAβ42 fluorescence is significantly decreased by 68%
(p = 0.0007; Tukey’s HSD post hoc test) compared to that
in capillaries from WT control mice. In contrast, luminal
FL-hAβ42 fluorescence in capillaries from NCZ-treated
hAPP mice was comparable to levels found in WT control mice (Δ = 27%; p = 0.27; Tukey’s HSD post hoc test).
Together, the data in Figs. 1 and 2 suggest that treatment of hAPP mice with NCZ protects P-gp protein
expression and transport activity at the blood-brain
barrier.
Effect of NCZ treatment on ALT levels

During the two-week treatment with NCZ, animals
were continuously monitored by daily health checks,
and we observed no NCZ-induced visible adverse
effects. We also determined alanine-aminotransferase
(ALT) activity levels in liver tissue samples from
treated and untreated animals after the 2-week dosing period to determine potential NCZ-induced liver
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a

b

Fig. 3 NCZ shows no effect on ALT activity levels. ALT activity levels
(mU/ml) in liver samples from WT, hAPP, hAPP-NCZ and hAPP-NCZ/
CSA mice. Data are given for each animal: WT (n = 10), hAPP (n = 15),
hAPP-NCZ (n = 15), hAPP-NCZ/CSA (n = 15). Statistics: ANOVA; Data
between groups are not significantly different

Effect of NCZ treatment on Aβ levels in hAPP mice
Fig. 2 Effect of NCZ on P-gp-Mediated hAβ42 transport. a
Representative confocal images of isolated brain capillaries showing
accumulation of fluorescein-hAβ42 in capillary lumens after a 1 hour
incubation (steady state; 5 µM fluorescein-hAβ42). b Data after digital
image analysis using ImageJ. Specific fluorescein-hAβ42 fluorescence
is the difference between total luminal fluorescein-hAβ42
fluorescence and fluorescein-hAβ42 fluorescence in the presence of
the P-gp-specific inhibitor PSC833 (5 µM). Statistics: Data per group
are given as mean ± S.E.M. for 10 capillaries from one preparation
(pooled tissue: WT (10 mice), hAPP (15 mice), hAPP-NCZ (15 mice),
hAPP-NCZ/CSA (15 mice)). Shown are arbitrary fluorescence units
(scale 0–255). ***, significantly lower than control, p < 0.001

toxicity. Increased ALT activity levels can be an indicator of liver damage and toxicity and are generally used
in the clinic to monitor overall health, in particular
to detect drug-induced liver toxicity [32]. ALT activity levels from all treatment groups ranged between
2,599 and 2,881 mU/ml; there was no significant difference between any of the groups (F3,51=1.1, p = 0.36;
ANOVA; Fig. 3).
These data show that the 2-week NCZ treatment
did not affect ALT activity, which suggests that NCZ
did not induce liver damage in the animals during the
treatment phase. More studies are necessary to fully
evaluate the safety of NCZ, especially with regard to a
long-term treatment regimen.

Next we evaluated the effect of NCZ treatment on hAβ40
and hAβ42 levels in plasma, brain capillary membranes,
and brain tissue.
We used ELISA to determine plasma hAβ40 and hAβ42
protein levels (Fig. 4a, b). hAβ40 levels were in the range
3,656–3,797 pg/ml with no significant difference between
groups (F2,42, p = 0.98; ANOVA). For hAβ42, we found
levels ranging from 200 to 244 pg/ml, also with no significant difference between groups (F2,42=0.13, p = 0.88;
ANOVA). This finding is consistent with rapid Aβ clearance from blood by the liver and the kidney [33]. Note
that samples from WT mice were not included in the
analysis since WT mice do not express human Aβ.
One characteristic of AD is accumulation of Aβ in
blood vessel walls [27, 34]. We therefore determined capillary-associated hAβ levels with immunohistochemistry.
Freshly isolated brain capillaries were immunostained for
hAβ40 and hAβ42, imaged with a confocal microscope,
followed by image analysis of capillary membranes. Brain
capillaries isolated from treated and untreated hAPP
mice stained positive for both hAβ40 and hAβ42 (Fig. 5a,
b). Image analysis revealed that NCZ-treatment lowered
capillary-associated hAβ40 by 37% (p = 0.0004; Tukey’s
HSD post hoc test) compared to capillaries from vehicletreated hAPP mice. For hAβ42, no difference was found
between treatment groups (p = 0.91; Tukey’s HSD post
hoc test).
Finally, we analyzed hAβ40 and hAβ42 brain levels by
Western blotting and ELISA. Western blotting showed
reduced hAβ40 and hAβ42 protein levels in brain tissue
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Fig. 4 NCZ treatment has no effect on hAβ40 and hAβ42 plasma
levels in hAPP mice. a hAβ40 levels (pg/ml) and b hAβ42 levels (pg/
ml) in plasma samples from WT, hAPP, hAPP-NCZ and hAPP-NCZ/
CSA mice. Data are given for each animal: WT (n = 10), hAPP (n = 15),
hAPP-NCZ (n = 15), hAPP-NCZ/CSA (n = 15). Statistics: ANOVA; Data
between groups are not significantly different

samples from NCZ-treated hAPP mice compared to
untreated hAPP mice (Fig. 6a). In contrast, hAβ protein levels in brain tissue from NCZ-treated mice that
also received CSA to control for P-gp transport activity appeared similar to those detected in brain tissue
from vehicle-treated hAPP mice. Using ELISA, we
found that in NCZ-treated hAPP mice hAβ40 brain levels were reduced by 48% (p < 0.0001; Tukey’s HSD post
hoc test) and hAβ42 brain levels were reduced by 30%
(p = 0.0008; Tukey’s HSD post hoc test) compared to
vehicle-treated hAPP mice (Fig. 6b, c).
In summary, our data presented here together with
our previously publish work support our proposed
mechanism that blocking P-gp internalization with
NCZ protects P-gp from proteasomal degradation,
which helps reduce Aβ brain load in hAPP mice (Fig. 7).
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Discussion
We previously showed that hAβ40 triggers (1) ubiquitination, (2) internalization, and (3) proteasomal degradation
of blood-brain barrier P-gp, which results in decreased
P-gp protein expression and transport function [22, 24].
We further demonstrated that preventing P-gp ubiquitination preserves P-gp protein expression and transport activity at the blood-brain barrier, which resulted
in lower Aβ brain levels in vivo [23]. Our present study
builds on this existing work and extends these findings by
targeting Aβ-driven P-gp internalization in vivo.
For the present study, we treated hAPP mice with the
microtubule inhibitor, nocodazole (NCZ), and evaluated
the effects of NCZ on P-gp protein expression and transport activity and hAβ burden. We found that isolated
brain capillaries from hAPP mice treated with NCZ had
P-gp expression and transport activity levels comparable to those from WT control mice (Figs. 1 and 2). No
adverse effects were noticed during nocodazole treatment, accordingly, ALT activity levels in liver samples
were similar across all groups. The absence of adverse
effects is likely due to the relatively short treatment phase
of 2 weeks. (Fig. 3). No difference in hAβ40 and hAβ42
levels was detected in plasma samples from treated and
un-treated hAPP mice (Fig. 4). We found that NCZ treatment decreased membrane-associated hAβ40 levels in
hAPP mice (Fig. 5) and show that hAβ40 and hAβ42 levels were significantly lower in brain samples from NCZtreated hAPP mice compared to those in untreated hAPP
mice and hAPP-NCZ/CSA control mice (Fig. 6). Based
on these data we conclude that NCZ treatment protects
P-gp protein expression and transport activity levels at
the blood-brain barrier and results in reduced Aβ levels
(Fig. 7). This effect is likely due to the inhibition of P-gp
internalization and degradation by NCZ. In the following sections we discuss our findings in the context of the
existing literature.
One mechanism that accounts for changes in P-gpmediated transport is trafficking between vesicular
compartments and the plasma membrane. Arias and colleagues were the first to report membrane trafficking of
several ABC transporters, including P-gp, bile salt export
pump (BSEP), and Mrp2 at the bile canalicular membrane
of hepatocytes [35, 36]. These authors showed cycling of
P-gp between intracellular pools and the plasma membrane by demonstrating insertion of P-gp into the canalicular membrane in response to cyclic AMP (cAMP) and
taurocholate. This effect was independent from protein
biosynthesis. In addition, the microtubule disruptor, colchicine, and the PI3 kinase inhibitor, wortmannin, inhibited membrane insertion of P-gp. On the other hand, it
was also demonstrated that cholestasis caused retrieval
of P-gp from the canalicular membrane into intracellular
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d

Fig. 5 NCZ lowers Aβ levels in brain capillaries. Representative confocal images of isolated brain capillaries immunostained for a hAβ40 and b
hAβ42. Data after digital image analysis of membrane-associated c hAβ40- and (D) hAβ42-immunofluorescence using ImageJ. Statistics: Data per
group are given as mean ± S.E.M. for 10 capillaries from one preparation [pooled tissue: WT (n = 10), hAPP (n = 15), hAPP-NCZ (n = 15), hAPP-NCZ/
CSA (n = 15)]. Shown are arbitrary fluorescence units (scale 0–255). For hAβ40 p < 0.001; ***, significantly lower than control. For hAβ42, data
between groups are not significantly different

vesicles [35, 37, 38]. Sai et al. visualized P-gp trafficking
between the pericanalicular region and the bile canalicular membrane in a hepatic cell line expressing GFPtagged P-gp [36]. These researchers also demonstrated an
involvement of microtubules in P-gp membrane trafficking. Their results show that in hepatocytes, vesicular trafficking of P-gp depends on microtubules and modulates
transport activity at the canalicular membrane. Recent
studies indicate that P-gp trafficking is also an important mechanism to regulate P-gp transport activity at the
blood-brain barrier. Hawkins and colleagues found that
the vascular endothelial growth factor (VEGF) triggers
removal of P-gp from the luminal membrane resulting in
decreased P-gp transport activity in brain capillaries [39].
This study provided first evidence that loss of P-gp transport activity can be due to P-gp internalization shifting the transporter into an intracellular compartment
where it no longer functions as an efflux transporter.
The effect of VEGF was blocked by nocodazole, whereas

proteasome inhibition had no effect. In a series of elegant
studies, McCaffrey, Tome and colleagues discovered
that peripheral inflammatory pain leads to caveolin1-mediated trafficking of P-gp at the blood-brain barrier
[40–42]. Caveolin-1 is a scaffolding protein that has been
shown to interact with P-gp [43]. In the case of peripheral pain, P-gp levels increased at the luminal membrane
of the brain capillary endothelium. In an in vitro study,
Noack et al. found that drugs such as mitomycin C trigger P-gp trafficking in the hCMEC/D3 cell line [44].
Redistribution of P-gp from intracellular pools to the
cell membrane occurred within 2 hours of incubation
with mitomycin C. Little is known about signaling steps
through which P-gp internalization and/or trafficking of
the transporter to the membrane occurs at the bloodbrain barrier. Work in liver and cancer cells showed that
Src kinase interacts with P-gp and that this interaction is
likely responsible for P-gp membrane localization [45].
Several studies found that Pim-1 kinase phosphorylates

Ding et al. Fluids Barriers CNS

(2021) 18:10

Page 10 of 13

a

b

c

Fig. 6 NCZ lowers Aβ brain levels. a Western Blot showing hAβ40 and hAβ42 protein expression levels in brain tissue samples from vehicle-treated
WT, vehicle-treated hAPP mice, hAPP mice dosed with 5 mg/kg NCZ and hAPP mice dosed with a combination of NCZ and CSA (5/25 mg/kg).
β-Actin was used as protein loading control. b hAβ40 and c hAβ42 levels (pg/ml) in brain tissue samples from hAPP, hAPP-NCZ and hAPP-NCZ/CSA
mice determined by ELISA. Statistics: ***, significantly lower than control, p < 0.001; **, significantly lower than control, p < 0.01

P-gp, which seems to be necessary for plasma membrane
localization of the transporter [46–49]. However, the
role Pim-1 plays in P-gp internalization and trafficking
still needs to be determined in more detail. We recently
observed that nanomolar concentrations of hAβ40 trigger P-gp degradation through the ubiquitin-proteasome
system [22, 24]. Inhibiting protein ubiquitination, protein trafficking, and the proteasome prevented hAβ40mediated decrease of P-gp protein expression and
transport activity. In a subsequent study we showed
that inhibiting the ubiquitin-activating enzyme E1 with

PYR41 prevented P-gp ubiquitination in vivo prevented
P-gp degradation and lowered Aβ brain levels [23]. The
present study expands this work by treating hAPP mice
with the microtubule inhibitor nocodazole in vivo and
demonstrates that P-gp expression and activity can be
protected with NCZ. In both studies, we used prefrontal cortex for Aβ quantification since this brain region is
highly affected in AD and shows early signs of Aβ deposition, while the remaining part of the cerebral cortex was
used to isolate brain capillaries. Comparing the data from
our previous study with PYR41 and the data from the
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activity depends to a large extent on vesicular trafficking,
and thus, a microtubule inhibitor would be needed that is
suitable and safe for the use in CNS disorders including
AD. Clearly, more work is needed to evaluate the potential therapeutic benefit of blocking P-gp internalization in
AD.
Acknowledgements
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Fig. 7 Proposed mechanism. Based on our data presented here
and our previously published data [22, 23], we propose that
blocking Aβ-induced internalization protects P-gp from proteasomal
degradation, which preserves P-gp protein expression and transport
activity and helps to reduce Aβ brain levels in hAPP mice

present study with nocodazole, we found no difference
between the effects of PYR41 and nocodazole on protecting P-gp from degradation and decreasing Aβ brain levels
(Aβ40: NCZ 48% vs. PYR41 53% and Aβ42: NCZ 30% vs.
PYR41 33%).
Drug combinations are often applied to treat complex
diseases and synergistic effects among different drugs
hold the promise to achieve larger effects with lower
doses and reduced side effect profiles [50]. Drugs acting
on the same signaling pathway by targeting different signaling molecules are more likely to produce synergistic
effects. Thus, based on our proposed signaling pathway
(Fig. 7), inhibiting both ubiquitination and internalization at the same time has the potential for synergistic
effects on preserving P-gp and lowering Aβ brain levels.
Clearly, future studies are needed to demonstrate such
potentially synergistic effects.

Conclusions
Based on our previously published work and the data
presented here, we conclude that inhibiting P-gp internalization with a microtubule inhibitor could be used to
protect P-gp from degradation which could help lower
Aβ brain levels in AD [22, 23]. Therefore, modulating
P-gp trafficking could be a potential new therapeutic
target to help protect P-gp at the blood-brain barrier in
AD. Currently, microtubule inhibitors are approved for
solid and hematologic cancers and include agents such as
taxanes, vinca alkaloids, and epothilones. Several drugs
including vincristine and colcemid are similar to nocodazole in that they interfere with microtubule polymerization [51]. Thus, there is the possibility of therapeutically
targeting P-gp trafficking in AD. However, neuronal
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